Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)

Launched by RENJI HOSPITAL · Jul 15, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment called YOLT-203 for people with Type 1 Primary Hyperoxaluria (PH1), a rare genetic condition that can lead to kidney problems. The study aims to find out if YOLT-203 is safe and how well it works in lowering the levels of oxalate in the blood after just one dose. The trial is open to participants aged 2 years and older who have specific gene mutations and meet certain health criteria, like having a certain level of kidney function and urinary oxalate levels.

Participants in this study will receive the treatment and will be monitored closely for up to a year to ensure their safety. They may also have the opportunity to receive a second dose if they are in the first group treated. After the main study is completed, there will be a long-term follow-up that could last up to 15 years. It’s important for potential participants to discuss their medical history and any medications they are taking with their doctor to see if they qualify for the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The age is ≥ 2 years old at the time of signing the informed consent.
• • Have AGXT gene mutations and be diagnosed with primary hyperoxaluria (PH1); eGFR ≥ 30 ml/min/1.73m2.
• • At least 2 times of 24-hour urinary oxalate excretion ≥ 0.7 mmol/1.73m2/day or the ratio of urinary oxalate to creatinine in a single urine collection must be higher than the upper limit of normal (ULN) for the corresponding age.
• • If treated with vitamin B6, the treatment has been stable for 90 days before enrollment in the study and is willing to maintain the stable treatment plan unchanged during the study.
• • The patient himself/herself or the guardian voluntarily signs the informed consent.
• Exclusion Criteria:
• • The investigator judges that there is clinical evidence of systemic extra-renal oxalate deposition.
• * Have any of the following laboratory parameter assessment results at screening:
• • 1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 x the upper limit of normal (ULN).
• • 2. Total bilirubin \> 1.5 x ULN. If the increase in total bilirubin is caused by diagnosed Gilbert's syndrome and the total bilirubin \< 2 x ULN, it is eligible.
• • 3. International normalized ratio (INR) \> 1.5 (Patients on oral anticoagulants \[such as warfarin\] and with INR \< 3.5 will be allowed to participate).
• • Known to have active human immunodeficiency virus (HIV) infection; or have evidence of current or chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection.
• • The estimated glomerular filtration rate (GFR) at screening is less than 30 mL/min/1.73m² (For patients ≥ 18 years old, it will be calculated according to the Modification of Diet in Renal Disease \[MDRD\] formula; for patients \< 18 years old, it will be calculated according to the Schwartz bedside formula). See the attachment.
• • Have received an investigational drug within the last 30 days or 5 half-lives (whichever is longer) before the first administration of the study drug, or have participated in the follow-up of another clinical study before randomization.
• • Have a history of kidney or liver transplantation.
• • According to the investigator's opinion, have other medical conditions or comorbidities that may interfere with study compliance or data interpretation.
• • Have a history of multiple drug allergies or allergic reaction history to oligonucleotides or LNP.
• • Have a history of subcutaneous injection intolerance.
• • Unwilling to comply with contraceptive requirements throughout the study participation period until 6 months after the end of the main study trial.
• • Female patients are pregnant, planning to become pregnant or breastfeeding.
• • Unwilling or unable to limit alcohol consumption throughout the study. Alcohol consumption during the study exceeds 2 units per day (1 unit: approximately 125 ml of wine = approximately 29 ml of spirits = approximately 284 ml of beer, will be excluded.
• • The investigator believes that there is a history of alcohol abuse within 12 months before screening.